Answers are grounded in this paper and cite their sources.
injections. In conclusion, the long-acting, unbiased compound 3 (hGIP(1-30-Cex)/Aib2/C16-diacid moiety in position 17), with retained activity for the human and rat GIPR, is suitable for bone remodeling studies in rats; hence, a useful tool compound for future research of GIP's therapeutic potential in bone-related diseases.
No takes yet. Share an insight, caveat, or question.
Tordrup et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: